초록 ▼

One embodiment of the invention is demineralized bone putty composition comprises: (1) demineralized bone matrix (DBM); and (2) a lipid fraction selected from the group consisting of lecithin and a mixture of lecithin and triglycerides containing unsaturated fatty acids. The putty composition is mo

One embodiment of the invention is demineralized bone putty composition comprises: (1) demineralized bone matrix (DBM); and (2) a lipid fraction selected from the group consisting of lecithin and a mixture of lecithin and triglycerides containing unsaturated fatty acids. The putty composition is moldable, biocompatible, slowly resorbable, insoluble in tissue fluids, and non-extrudable. The composition delivers a biologically active product to animals and humans that will enhance bone formation at sites where bone is lost, deficient, or present in suboptimal amounts. The composition can further comprise calcium, an antioxidant such as Vitamin E or Vitamin C, or a hydrophilic polymer such as methylcellulose, a methylcellulose derivative, carboxymethyl cellulose, or hydroxypropyl methylcellulose. A second embodiment of the invention is a demineralized bone paste composition comprising: (1) about 15% to about 75% of an emulsion carrier, such as an aqueous phase; and (2) a bone-material-containing phase comprising: (a) demineralized bone matrix (DBM); and (b) an emulsifier component that is compatible with lipids. This bone paste composition is moldable, biocompatible, slowly resorbable, miscible with bone graft materials, soluble or partially soluble in tissue fluids, and extrudable.

대표청구항 ▼

I claim: 1. A demineralized bone paste composition comprising: (a) about 25% to about 75% of an emulsion carrier; and (b) a bone-material-containing phase comprising: (i) demineralized bone matrix (DBM); and (ii) an emulsifier component that is compatible with lipids; such that the paste is moldabl

I claim: 1. A demineralized bone paste composition comprising: (a) about 25% to about 75% of an emulsion carrier; and (b) a bone-material-containing phase comprising: (i) demineralized bone matrix (DBM); and (ii) an emulsifier component that is compatible with lipids; such that the paste is moldable, biocompatible, slowly resorbable, miscible with bone graft materials, soluble in tissue fluids, and extrudable; and wherein the emulsifier component comprises a mixture of lecithin and triglycerides containing unsaturated fatty acids. 2. The bone paste composition of claim 1 wherein the emulsion carrier comprises from about 15% to about 55% of the composition. 3. The bone paste composition of claim 2 wherein the emulsion carrier comprises from about 25% to about 45% of the composition. 4. The bone paste composition of claim 3 wherein the emulsion carrier comprises about 35% of the composition. 5. The bone paste composition of claim 1 wherein the emulsion carrier comprises an aqueous phase. 6. The bone paste composition of claim 1 wherein the emulsion carrier comprises a polar but nonaqueous solvent. 7. The bone paste composition of claim 6 wherein the polar but nonaqueous solvent is selected from the group consisting of dimethylformamide (DMF), dimethylsulfoxide (DMSO), and acetonitrile. 8. The bone paste composition of claim 5 wherein the aqueous phase comprises from about 15% to about 55% of the composition. 9. The bone paste composition of claim 8 wherein the aqueous phase comprises from about 25% to about 45% of the composition. 10. The bone paste composition of claim 9 wherein the aqueous phase comprises about 35% of the composition. 11. The bone paste composition of claim 5 wherein the aqueous phase comprises an aqueous liquid selected from the group consisting of water, saline, and an aqueous electrolyte. 12. The bone paste composition of claim 11 wherein the aqueous liquid is water. 13. The bone paste composition of claim 11 wherein the aqueous liquid is saline. 14. The bone paste composition of claim 11 wherein the aqueous liquid is an aqueous electrolyte. 15. The bone paste composition of claim 1 wherein the bone-material-containing phase comprises from about 20% to about 80% of DBM and from about 20% to about 80% of the emulsifier component. 16. The bone paste composition of claim 15 wherein the bone-material-containing phase comprises about 30% to about 40% of DBM. 17. The bone paste composition of claim 15 wherein the bone-material-containing phase comprises about 35% to about 40% of DBM. 18. The bone paste composition of claim 1 wherein the unsaturated fatty acids are about 25% mono-unsaturated fatty acids, about 59% di-unsaturated fatty acids, and about 1% of fatty acids with higher degrees of unsaturation, wherein the mono-unsaturated fatty acids comprise oleic acid, the di-unsaturated fatty acids comprise linoleic acid, and the fatty acids with higher degrees of unsaturation comprise linolenic acid. 19. The bone paste composition of claim 1 wherein the mixture of lecithin and triglycerides containing unsaturated fatty acids is about a 1:1 mixture. 20. The bone paste composition of claim 1 wherein the mixture of lecithin and triglycerides containing unsaturated fatty acids is about a 65:35 mixture. 21. The bone paste composition of claim 18 wherein the unsaturated fatty acids are from corn oil. 22. The bone paste composition of claim 21 wherein the lecithin and unsaturated fatty acids from corn oil is about 80:20. 23. The bone paste composition of claim 21 wherein the lecithin and unsaturated fatty acids from corn oil is about 60:40. 24. The bone paste composition of claim 21 wherein the ratio of lecithin and unsaturated fatty acids from corn oil is about 65:35. 25. The bone paste composition of claim 1 wherein the composition further comprises a calcium salt. 26. The bone paste composition of claim 25 wherein the calcium salt is from about 0.1% to about 2.0%. 27. The bone paste composition of claim 26 wherein the calcium salt is from about 0.5% to about 2.0%. 28. The bone paste composition of claim 25 wherein the calcium salt is selected from the group consisting of CaCO2 and Ca3(PO4)2. 29. The bone paste composition of claim 28 wherein the calcium salt is CaCO2. 30. The bone paste composition of claim 28 wherein the calcium salt is Ca3(PO4)2. 31. The bone paste composition of claim 1 wherein the composition further comprises at least one antioxidant selected from the group consisting of vitamin E and vitamin C. 32. The bone paste composition of claim 31 wherein the antioxidant is vitamin E. 33. The bone paste composition of claim 32 wherein the vitamin E is tocopherol. 34. The bone paste composition of claim 32 wherein the vitamin E comprises from about 0.01% to about 1.0% of the composition. 35. The bone paste composition of claim 34 wherein the vitamin E comprises about 0.1% of the composition. 36. The bone paste composition of claim 31 wherein the antioxidant is vitamin C. 37. The bone paste composition of claim 36 wherein the vitamin C comprises from about 0.01% to about 2.0% of the composition. 38. The bone paste composition of claim 37 wherein the vitamin C comprises from about 0.1% to about 0.5% of the composition. 39. The bone paste composition of claim 37 wherein the vitamin C comprises about 0.2% of the composition. 40. The bone paste composition of claim 1 wherein the composition further comprises at least one preservative in a quantity sufficient to retard bacterial growth. 41. The bone paste composition of claim 40 wherein the preservative is selected from the group consisting of methylparaben, ethylparaben, propylparaben, butylparaben, benzyl alcohol, chlorphenesin, and diazolidinyl urea. 42. The bone paste composition of claim 1 wherein the composition further comprises at least one ingredient selected from the group consisting of methylcellulose, carboxymethylcellulose, and hydroxypropyl methylcellulose. 43. The bone paste composition of claim 42 wherein the ingredient is methylcellulose. 44. The bone paste composition of claim 43 wherein the methylcellulose comprises from about 0.1% to about 5% of the composition. 45. The bone paste composition of claim 42 wherein the ingredient is carboxymethyl cellulose. 46. The bone paste composition of claim 45 wherein the carboxymethyl cellulose comprises from about 0.1% to about 5% of the composition. 47. The bone paste composition of claim 42 wherein the ingredient is hydroxypropyl methylcellulose. 48. The bone paste composition of claim 1 wherein the DBM is human DBM. 49. The bone paste composition of claim 1 wherein the DBM is rat DBM. 50. The bone paste composition of claim 1 wherein the DBM is DBM isolated from an animal species selected from the group consisting of cow, horse, pig, dog, cat, sheep, and another socially or economically important animal species. 51. The bone paste composition of claim 1 wherein the DBM is delipidated. 52. The bone paste composition of claim 51 wherein the delipidation is performed by treatment with a mixture of chloroform and methanol. 53. The bone paste composition of claim 1 wherein the composition further comprises a long-chain saturated fatty acid. 54. The bone paste composition of claim 53 wherein the long-chain saturated fatty acid is palmitic acid. 55. The bone paste composition of claim 1 wherein the lecithin is a phospholipid. 56. The bone paste composition of claim 55 wherein the phospholipid is selected from the group consisting of phosphatidyl seine, phosphatidyl ethanolamine, phosphatidyl inositol, diphosphatidyl glycerol, and sphingomyelin. 57. The bone paste composition of claim 1 wherein the composition further comprises an antibiotic in the aqueous phase. 58. The bone paste composition of claim 53 wherein the antibiotic is selected from the group consisting of tetracycline, erythromycin, penicillins, methicillin, nafcillin, oxacillin, cloxacillin, dicloxacillin, ampicillin, amoxicillin, bacampicillin, carbenicillin, ticarcillin, mezlocillin, piperacillin, cephalosporins, gentamicin, tobramycin, amikacin, netilmycin, kanamycin, neomycin, clarithromycin, azithromycin, clindamycin, spectinomycin, vancomycin, and rifamycins. 59. The bone paste composition of claim 1 wherein the composition further comprises a growth factor or a splice variant, a variant produced by proteolysis, a variant produced by the presence or lack of glycosylation, a naturally-occurring isoform, a naturally-occurring mutation or allelic variant, or a mutein of a growth factor. 60. The bone paste composition of claim 1 wherein the composition further comprises a growth factor. 61. The bone paste composition of claim 60 wherein the growth factor is selected from the group consisting of an interleukin, a bone morphogenetic protein (BMP), BDNF, TGFα1, TGFβ1, TGFβ2, aFGF, bFGF, G-CSF, GDNF, GM-CSF, growth hormone, HCC-1, IGF I, IGF II, M-CSF, and SCF. 62. The bone paste composition of claim 61 wherein the growth factor is a BMP. 63. The bone paste composition of claim 62 wherein the BMP is a BMP sharing a common structural motif and that is a disulfide-linked dimeric protein. 64. The bone paste composition of claim 63 wherein the BMP is selected from the group consisting of BMP-2, BMP-3, BMP-3b, BMP-4, BMP-5, BMP-6, BMP-7, BMP-8, BMP-8B, GDF-3, GDF-5, GDF-6, GDF-7, GDF-8, GDF-9, GDF-10, and nodal. 65. The bone paste composition of claim 64 wherein the BMP is BMP-3. 66. The bone paste composition of claim 1 wherein the composition further comprises a fusion protein that incorporates a growth factor. 67. The bone paste composition of claim 66 wherein the growth factor is a BMP. 68. The bone paste composition of claim 67 wherein the BMP is a BMP sharing a common structural motif and that is a disulfide-linked dimeric protein. 69. The bone paste composition of claim 68 wherein the BMP is selected from the group consisting of BMP-2, BMP-3, BMP-3b, BMP-4, BMP-5, BMP-6, BMP-7, BMP-8, BMP-8B, GDF-3, GDF-5, GDF-6, GDF-7, GDF-8, GDF-9, GDF-10, and nodal. 70. The bone paste composition of claim 69 wherein the BMP is BMP-3. 71. The bone paste composition of claim 1 wherein the composition further comprises a platelet glue wound sealant comprising: (i) a plasma-buffy coat concentrate comprising plasma, platelets, and calcium; and (ii) a fibrinogen activator in a concentration sufficient to initiate clot formation. 72. The bone paste composition of claim 71 wherein the fibrinogen activator is selected from the group consisting of thrombin and batroxobin. 73. The bone paste composition of claim 71 wherein the platelets are present at a concentration of at least about 1.0��109 cells/ml and the plasma-buffy coat concentrate contains fibrinogen at a concentration of at least about 5 mg/ml. 74. The bone paste composition of claim 73 wherein the platelets are present at a concentration of from about 1.0��109 cells/ml to about 2.5��109 cells/ml and the plasma-buffy coat concentrate contains fibrinogen at a concentration of from about 5 mg/ml to about 15 mg/ml. 75. The bone paste composition of claim 71 wherein the platelet glue wound sealant further comprises leukocytes. 76. The bone paste composition of claim 75 wherein the leukocytes are present at a concentration of at least 3.0��107 cells/ml. 77. The bone paste composition of claim 76 wherein the leukocytes are present at a concentration of from about 3.0��107 cells/ml to about 6.0��107 cells/ml. 78. The bone paste composition of claim 75 wherein the leukocytes comprise from about 60% to about 70% of lymphocytes, from about 15% to about 25% of monocytes, and from about 5% to about 25% of neutrophils. 79. The bone paste composition of claim 1 wherein the composition is compatible with a suspension of autologous bone marrow. 80. A composition comprising: (a) the demineralized bone paste composition of claim 1; and b) another bone graft material compatible and blendable with the demineralized bone paste composition. 81. The composition of claim 80 wherein the bone graft material is selected from the group consisting of autograft bone material, allograft bone material, and artificial bone graft material. 82. The composition of claim 81 wherein the bone graft material is autograft bone material. 83. The composition of claim 81 wherein the bone graft material is allograft bone material. 84. The composition of claim 81 wherein the bone graft material is artificial bone graft material. 85. The composition of claim 84 wherein the artificial bone graft material is selected from the group consisting of coralline calcium salt based porous ceramics, aluminum calcium phosphate, plaster of paris, hydroxyapatite, tricalcium phosphate, ferric-calcium-phosphorous oxides, zinc-calcium-phosphorous oxides, and zinc sulfate-calcium-phosphorous oxides. 86. The composition of claim 85 wherein the artificial bone graft material is coralline calcium salt based porous ceramics.